Anti-Canine PD-L1 [Clone JC071]

Recombinant extracellular domain of canine PD-L1 fused with the Fc domain of human IgG1 expressed in D. melanogaster S2 cells.

PBS, pH 7.4.

Liquid

Purified by Protein G affinity chromatography

This antibody is stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

Next Day 2-8°C

Mouse Monoclonal Antibody specific to Canine PD-L1

Each year, thousands of dogs are diagnosed with cancer. Canine cancers bear many of the hallmarks of human cancers including tissue location, tumor progression, and response to chemotherapy and radiation. Unfortunately, canine lymphocyte populations are not as well defined as human lymphocytes, and reagents that target immune checkpoint pathways are not yet widely available for veterinary research. Interruption of the programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) pathway is an established and effective therapeutic strategy in human oncology and may be effective for treating canine cancers as well.

Choi JW et al. 2020 Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function. PLoS One. 2020; 15(7): e0235518.